ERG Addendum: Corrections to the calculation of the ranibizumab PAS

The ERG report tables 75, 77, 78, 79, 80 and 81 have incorrectly calculated the impact of the various ranibizumab PAS percentages. These discounted both the ranibizumab price and the ranibizumab administration cost. The correct figures which just discount the ranibizumab price are presented below.

Table 75 ERG base case results: aflibercept versus ranibizumab: ranibizumab PAS discounts

Δ QALYs	Rani. PAS	Δ Costs	ICER	Rani. PAS	Δ Costs	ICER
0.091	5%	-£3,663	Dominant	55%	£3,608	£39,528
	10%	-£2,936	Dominant	60%	£4,335	£47,494
	15%	-£2,209	Dominant	65%	£5,063	£55,459
	20%	-£1,481	Dominant	70%	£5,790	£63,424
	25%	-£754	Dominant	75%	£6,517	£71,389
	30%	-£27	Dominant	80%	£7,244	£79,354
	35%	£700	£7,667	85%	£7,971	£87,320
	40%	£1,427	£15,633	90%	£8,698	£95,285
	45%	£2,154	£23,598	95%	£9,425	£103,250
	50%	£2,881	£31,563	100%	£10,152	£111,215

Table 77 ERG sensitivity analyses: aflibercept vs ranibizumab: with aflibercept PAS and ranibizumab PAS 5% to 20%

Ranibizumab PAS		5%		10%		15%		20%	
	Δ QALYs	Δ Costs	ICER	Δ Costs	ICER	Δ Costs	ICER	Δ Costs	ICER
Base case	0.091	-£4,390	Dominant	-£3,663	Dominant	-£2,936	Dominant	-£2,209	Dominant
RR excl. VISTA	0.073	-£4,285	Dominant	-£3,558	Dominant	-£2,831	Dominant	-£2,104	Dominant
RR excl. REVEAL	0.152	-£3,384	Dominant	-£2,694	Dominant	-£2,005	Dominant	-£1,315	Dominant
RR excl. VISTA & REVEAL	0.072	-£3,379	Dominant	-£2,687	Dominant	-£1,995	Dominant	-£1,303	Dominant
EQ-5D QoL OLS	0.012	-£4,390	Dominant	-£3,663	Dominant	-£2,936	Dominant	-£2,209	Dominant
EQ-5D QoL GEE	0.008	-£4,390	Dominant	-£3,663	Dominant	-£2,936	Dominant	-£2,209	Dominant
Brown 1999 QoL	0.061	-£4,390	Dominant	-£3,663	Dominant	-£2,936	Dominant	-£2,209	Dominant
Brown 2000 QoL	0.106	-£4,390	Dominant	-£3,663	Dominant	-£2,936	Dominant	-£2,209	Dominant
46% FEI baseline	0.082	-£4,026	Dominant	-£3,369	Dominant	-£2,711	Dominant	-£2,054	Dominant
Company mid letters	0.098	-£4,390	Dominant	-£3,663	Dominant	-£2,936	Dominant	-£2,209	Dominant
Blind res. care 20%	0.091	-£4,381	Dominant	-£3,654	Dominant	-£2,927	Dominant	-£2,200	Dominant
FEI DMO Tx 0%	0.064	-£3,224	Dominant	-£2,722	Dominant	-£2,220	Dominant	-£1,718	Dominant
FEI DMO Tx 100%	0.118	-£5,556	Dominant	-£4,604	Dominant	-£3,651	Dominant	-£2,699	Dominant
Tx share monit. 50%	0.091	-£4,269	Dominant	-£3,542	Dominant	-£2,815	Dominant	-£2,088	Dominant
SE share NSE 0%	0.091	-£4,667	Dominant	-£3,940	Dominant	-£3,213	Dominant	-£2,486	Dominant
No one eye blind mort.	0.087	-£4,395	Dominant	-£3,668	Dominant	-£2,940	Dominant	-£2,213	Dominant
8.1 Rani. Tx yr1	0.091	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
4.0 Afli Tx yr2	0.091	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
2.3 Rani. Afli. Tx yr3	0.091	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
8.0 Rani. Monit. Yr1	0.091	-£3,836	Dominant	-£3,109	Dominant	-£2,382	Dominant	-£1,655	Dominant

Table 78 ERG sensitivity analyses: aflibercept vs ranibizumab: with aflibercept PAS and ranibizumab PAS 25% to 40%

Ranibizumab PAS		25%		30%		35%		40%	
	Δ QALYs	Δ Costs	ICER	Δ Costs	ICER	Δ Costs	ICER	Δ Costs	ICER
Base case	0.091	-£754	Dominant	-£27	Dominant	£700	£7,667	£1,427	£15,633
RR excl. VISTA	0.073	-£650	Dominant	£77	£1,056	£804	£11,012	£1,531	£20,967
RR excl. REVEAL	0.152	£64	£422	£753	£4,973	£1,443	£9,524	£2,133	£14,075
RR excl. VISTA & REVEAL	0.072	£81	£1,129	£774	£10,728	£1,466	£20,328	£2,158	£29,928
EQ-5D QoL OLS	0.012	-£754	Dominant	-£27	Dominant	£700	£56,402	£1,427	£114,995
EQ-5D QoL GEE	0.008	-£754	Dominant	-£27	Dominant	£700	£86,915	£1,427	£177,205
Brown 1999 QoL	0.061	-£754	Dominant	-£27	Dominant	£700	£11,548	£1,427	£23,545
Brown 2000 QoL	0.106	-£754	Dominant	-£27	Dominant	£700	£6,597	£1,427	£13,449
46% FEI baseline	0.082	-£740	Dominant	-£82	Dominant	£575	£6,993	£1,232	£14,988
Company mid letters	0.098	-£754	Dominant	-£27	Dominant	£700	£7,110	£1,427	£14,497
Blind res. care 20%	0.091	-£746	Dominant	-£19	Dominant	£709	£7,762	£1,436	£15,727
FEI DMO Tx 0%	0.064	-£715	Dominant	-£213	Dominant	£289	£4,485	£791	£12,275
FEI DMO Tx 100%	0.118	-£794	Dominant	£158	£1,341	£1,111	£9,402	£2,063	£17,463
Tx share monit. 50%	0.091	-£634	Dominant	£93	£1,021	£820	£8,986	£1,547	£16,951
SE share NSE 0%	0.091	-£1,031	Dominant	-£304	Dominant	£423	£4,632	£1,150	£12,597
No one eye blind mort.	0.087	-£759	Dominant	-£31	Dominant	£696	£8,034	£1,423	£16,431
8.1 Rani. Tx yr1	0.091	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
4.0 Afli Tx yr2	0.091	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
2.3 Rani. Afli. Tx yr3	0.091	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
8.0 Rani. Monit. Yr1	0.091	-£201	Dominant	£526	£5,765	£1,253	£13,730	£1,980	£21,695

Table 79 ERG sensitivity analyses: aflibercept vs ranibizumab: with aflibercept PAS and ranibizumab PAS 45% to 60%

Ranibizumab PAS		45%		50%		55%		60%	
	Δ QALYs	Δ Costs	ICER	Δ Costs	ICER	Δ Costs	ICER	Δ Costs	ICER
Base case	0.091	£2,154	£23,598	£2,881	£31,563	£3,608	£39,528	£4,335	£47,494
RR excl. VISTA	0.073	£2,258	£30,923	£2,985	£40,878	£3,713	£50,834	£4,440	£60,789
RR excl. REVEAL	0.152	£2,822	£18,626	£3,512	£23,177	£4,201	£27,728	£4,891	£32,279
RR excl. VISTA & REVEAL	0.072	£2,850	£39,528	£3,542	£49,128	£4,234	£58,728	£4,926	£68,327
EQ-5D QoL OLS	0.012	£2,154	£173,588	£2,881	£232,181	£3,608	£290,774	£4,335	£349,366
EQ-5D QoL GEE	0.008	£2,154	£267,496	£2,881	£357,787	£3,608	£448,078	£4,335	£538,369
Brown 1999 QoL	0.061	£2,154	£35,543	£2,881	£47,540	£3,608	£59,537	£4,335	£71,534
Brown 2000 QoL	0.106	£2,154	£20,302	£2,881	£27,155	£3,608	£34,008	£4,335	£40,861
46% FEI baseline	0.082	£1,889	£22,984	£2,547	£30,979	£3,204	£38,975	£3,861	£46,971
Company mid letters	0.098	£2,154	£21,884	£2,881	£29,271	£3,608	£36,657	£4,335	£44,044
Blind res. care 20%	0.091	£2,163	£23,692	£2,890	£31,657	£3,617	£39,623	£4,344	£47,588
FEI DMO Tx 0%	0.064	£1,293	£20,064	£1,794	£27,854	£2,296	£35,644	£2,798	£43,433
FEI DMO Tx 100%	0.118	£3,016	£25,524	£3,968	£33,585	£4,921	£41,646	£5,873	£49,707
Tx share monit. 50%	0.091	£2,274	£24,916	£3,002	£32,882	£3,729	£40,847	£4,456	£48,812
SE share NSE 0%	0.091	£1,877	£20,562	£2,604	£28,527	£3,331	£36,493	£4,058	£44,458
No one eye blind mort.	0.087	£2,150	£24,828	£2,877	£33,225	£3,605	£41,622	£4,332	£50,019
8.1 Rani. Tx yr1	0.091	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
4.0 Afli Tx yr2	0.091	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
2.3 Rani. Afli. Tx yr3	0.091	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
8.0 Rani. Monit. Yr1	0.091	£2,708	£29,660	£3,435	£37,626	£4,162	£45,591	£4,889	£53,556

Table 80 ERG sensitivity analyses: aflibercept vs ranibizumab: with aflibercept PAS and ranibizumab PAS 65% to 80%

Ranibizumab PAS		65%		70%		75%		80%	
	Δ QALYs	Δ Costs	ICER	Δ Costs	ICER	Δ Costs	ICER	Δ Costs	ICER
Base case	0.091	£5,063	£55,459	£5,790	£63,424	£6,517	£71,389	£7,244	£79,354
RR excl. VISTA	0.073	£5,167	£70,745	£5,894	£80,700	£6,621	£90,656	£7,348	£100,611
RR excl. REVEAL	0.152	£5,580	£36,830	£6,270	£41,382	£6,960	£45,933	£7,649	£50,484
RR excl. VISTA & REVEAL	0.072	£5,619	£77,927	£6,311	£87,527	£7,003	£97,127	£7,695	£106,727
EQ-5D QoL OLS	0.012	£5,063	£407,959	£5,790	£466,552	£6,517	£525,145	£7,244	£583,738
EQ-5D QoL GEE	0.008	£5,063	£628,659	£5,790	£718,950	£6,517	£809,241	£7,244	£899,532
Brown 1999 QoL	0.061	£5,063	£83,531	£5,790	£95,528	£6,517	£107,525	£7,244	£119,522
Brown 2000 QoL	0.106	£5,063	£47,714	£5,790	£54,566	£6,517	£61,419	£7,244	£68,272
46% FEI baseline	0.082	£4,518	£54,966	£5,175	£62,962	£5,833	£70,957	£6,490	£78,953
Company mid letters	0.098	£5,063	£51,431	£5,790	£58,817	£6,517	£66,204	£7,244	£73,591
Blind res. care 20%	0.091	£5,071	£55,553	£5,798	£63,518	£6,525	£71,483	£7,253	£79,449
FEI DMO Tx 0%	0.064	£3,300	£51,223	£3,802	£59,012	£4,303	£66,802	£4,805	£74,591
FEI DMO Tx 100%	0.118	£6,825	£57,768	£7,778	£65,829	£8,730	£73,890	£9,683	£81,951
Tx share monit. 50%	0.091	£5,183	£56,777	£5,910	£64,742	£6,637	£72,708	£7,364	£80,673
SE share NSE 0%	0.091	£4,785	£52,423	£5,513	£60,388	£6,240	£68,353	£6,967	£76,319
No one eye blind mort.	0.087	£5,059	£58,416	£5,786	£66,813	£6,513	£75,210	£7,241	£83,608
8.1 Rani. Tx yr1	0.091	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
4.0 Afli Tx yr2	0.091	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
2.3 Rani. Afli. Tx yr3	0.091	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
8.0 Rani. Monit. Yr1	0.091	£5,616	£61,521	£6,343	£69,486	£7,070	£77,452	£7,797	£85,417

Table 81 ERG sensitivity analyses: aflibercept vs ranibizumab: with aflibercept PAS and ranibizumab PAS 85% to 100%

Ranibizumab PAS		85%		90%		95%		100%	
	Δ QALYs	Δ Costs	ICER	Δ Costs	ICER	Δ Costs	ICER	Δ Costs	ICER
Base case	0.091	£7,971	£87,320	£8,698	£95,285	£9,425	£103,250	£10,152	£111,215
RR excl. VISTA	0.073	£8,075	£110,567	£8,802	£120,522	£9,529	£130,478	£10,256	£140,433
RR excl. REVEAL	0.152	£8,339	£55,035	£9,028	£59,586	£9,718	£64,137	£10,407	£68,688
RR excl. VISTA & REVEAL	0.072	£8,387	£116,327	£9,079	£125,927	£9,771	£135,526	£10,464	£145,126
EQ-5D QoL OLS	0.012	£7,971	£642,331	£8,698	£700,924	£9,425	£759,517	£10,152	£818,109
EQ-5D QoL GEE	0.008	£7,971	£989,822	£8,698	£1,080,113	£9,425	£1,170,404	£10,152	£1,260,695
Brown 1999 QoL	0.061	£7,971	£131,519	£8,698	£143,516	£9,425	£155,513	£10,152	£167,510
Brown 2000 QoL	0.106	£7,971	£75,125	£8,698	£81,978	£9,425	£88,831	£10,152	£95,684
46% FEI baseline	0.082	£7,147	£86,949	£7,804	£94,944	£8,462	£102,940	£9,119	£110,935
Company mid letters	0.098	£7,971	£80,977	£8,698	£88,364	£9,425	£95,751	£10,152	£103,137
Blind res. care 20%	0.091	£7,980	£87,414	£8,707	£95,379	£9,434	£103,344	£10,161	£111,310
FEI DMO Tx 0%	0.064	£5,307	£82,381	£5,809	£90,171	£6,311	£97,960	£6,812	£105,750
FEI DMO Tx 100%	0.118	£10,635	£90,012	£11,587	£98,073	£12,540	£106,134	£13,492	£114,195
Tx share monit. 50%	0.091	£8,091	£88,638	£8,818	£96,603	£9,546	£104,569	£10,273	£112,534
SE share NSE 0%	0.091	£7,694	£84,284	£8,421	£92,249	£9,148	£100,214	£9,875	£108,180
No one eye blind mort.	0.087	£7,968	£92,005	£8,695	£100,402	£9,422	£108,799	£10,149	£117,196
8.1 Rani. Tx yr1	0.091	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
4.0 Afli Tx yr2	0.091	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
2.3 Rani. Afli. Tx yr3	0.091	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
8.0 Rani. Monit. Yr1	0.091	£8,524	£93,382	£9,252	£101,347	£9,979	£109,313	£10,706	£117,278